Veru (NASDAQ:VERU) Posts Earnings Results

Veru (NASDAQ:VERU) posted its quarterly earnings data on Monday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.02, FiscalAI reports.

Here are the key takeaways from Veru’s conference call:

• PLATEAU trial fully enrolled with 239 older patients receiving semaglutide and enobosarm; the 32-week interim analysis is expected in Q1 2027, with final results targeted for Q4 2027.
• Veru received a USPTO notice of allowance for enobosarm’s use with semaglutide and other weight-loss drugs to preserve lean mass, enhance fat loss, and improve physical function, with potential patent protection through at least October 2044.
• Novo Nordisk will supply Wegovy at no charge for the PLATEAU study, while Veru retains global enobosarm rights; the agreement also gives Novo Nordisk a right of first negotiation for future combinations with its GLP-1 products.
• Management is positioning enobosarm for older patients with obesity at risk of muscle and physical-function decline from GLP-1 treatment, citing a potential Medicare population of more than 20 million people, though commercial opportunity remains dependent on clinical and regulatory success.
• Veru remains unprofitable and used $20.6 million in operating cash during the first nine months of fiscal 2026; its $23.9 million cash and restricted-cash balance is expected to fund operations only beyond the PLATEAU interim analysis, indicating possible future financing needs.

Veru Trading Up 0.7%

Shares of VERU opened at $2.79 on Wednesday. Veru has a twelve month low of $2.05 and a twelve month high of $7.33. The firm has a market capitalization of $44.78 million, a P/E ratio of -3.13 and a beta of -1.15. The stock’s fifty day simple moving average is $2.73 and its 200 day simple moving average is $2.50.

Hedge Funds Weigh In On Veru

A number of large investors have recently modified their holdings of VERU. NewEdge Advisors LLC lifted its stake in shares of Veru by 388.7% in the 4th quarter. NewEdge Advisors LLC now owns 70,525 shares of the company’s stock valued at $151,000 after purchasing an additional 56,095 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in Veru during the 4th quarter worth approximately $75,000. Blair William & Co. IL raised its holdings in Veru by 26.3% in the fourth quarter. Blair William & Co. IL now owns 48,000 shares of the company’s stock valued at $103,000 after buying an additional 10,000 shares during the period. Alyeska Investment Group L.P. purchased a new position in Veru in the fourth quarter valued at approximately $2,140,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Veru during the third quarter valued at approximately $110,000. 47.16% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on VERU. Oppenheimer decreased their price target on Veru from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, May 15th. Wall Street Zen raised shares of Veru to a “hold” rating in a research note on Sunday, July 12th. Weiss Ratings upgraded shares of Veru from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $25.00 target price on shares of Veru in a research report on Thursday, June 4th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $23.00.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company headquartered in Miami, Florida. The company is dedicated to the development and commercialization of novel therapies in the fields of oncology and infectious disease. Veru’s research strategy centers on advancing small-molecule and biologic candidates through clinical trials, leveraging its in-house manufacturing and formulation capabilities as well as strategic partnerships to support late-stage development.

The company’s lead product candidate is sabizabulin (VERU-111), an oral, microtubule-disrupting agent undergoing pivotal trials for indications that include metastatic castration-resistant prostate cancer and hospitalized patients with severe COVID-19.